Erythropoietin and prematurity--where do we stand?

Area of Science:

• Neonatology
• Hematology
• Pediatric Medicine

Background:

• Anemia of prematurity remains a significant concern in neonatal intensive care.
• Erythropoietin (EPO) treatment efficacy for preventing transfusions in preterm infants is debated.
• Current management requires a multifactorial approach to optimize erythrocytic mass.

Purpose of the Study:

• To evaluate the impact of a revised Erythropoietin (EPO) and iron (Fe) treatment protocol on transfusion rates in preterm infants.
• To determine optimal criteria for EPO+Fe administration in premature infants.
• To assess the effect of EPO+Fe on reducing the number of blood donors rather than just transfusions.

Main Methods:

• A protocol was implemented limiting EPO+Fe to specific gestational age and birth weight criteria, including infants with severe neonatal disease.
• Outcomes were compared before and after the protocol implementation over defined periods.
• Standardized transfusion protocols were followed for all preterm infants in the study.

Main Results:

• A significant decrease in the percentage of infants eligible for EPO+Fe treatment was observed post-protocol (40.3% vs. 85.9%).
• No significant change in the overall percentage of transfusions was noted between the two periods.
• The study suggests refined criteria for EPO+Fe use, focusing on very low birth weight infants or those with risk factors.

Conclusions:

• Erythropoietin (EPO) and iron (Fe) treatment for anemia of prematurity should be reserved for specific high-risk preterm infants, particularly those under 1000g birth weight or between 1000-1250g with risk factors.
• The optimal timing for initiating EPO+Fe is 3-7 days of life, with specific dosing and duration based on gestational age.
• Multifactorial management of anemia of prematurity, including minimizing phlebotomy losses and optimizing nutrition, remains crucial alongside targeted EPO+Fe therapy.